• 中国核心期刊数据库收录期刊
  • 中文科技期刊数据库收录期刊
  • 中国期刊全文数据库收录期刊
  • 中国学术期刊综合评价数据库统计源期刊等

快速检索引用检索图表检索高级检索

中国医药导刊 ›› 2024, Vol. 26 ›› Issue (12): 1241-1245.

• 临床医药 • 上一篇    下一篇

丁苯酞软胶囊治疗穿支动脉粥样硬化性脑梗死合并早期抑郁症的临床疗效观察

王文娟, 陈鹏, 曹雪, 福婷*   

  1. 陕西省咸阳市中心医院,陕西 咸阳 712000
  • 收稿日期:2024-09-29 修回日期:2024-12-05 出版日期:2024-12-28 发布日期:2024-12-28
  • 基金资助:
    陕西省中医药管理局项目(SZY-KJCYC-2022-YJ);陕西省咸阳市重点研发项目(2021ZDYF-SF-0047)

Clinical Efficacy of Butylphthalide Soft Capsule in the Treatment of Branch Atheromatous Disease Complicated with Early Depression

  1. Xianyang Central Hospital Shaanxi Xianyang 712000, China
  • Received:2024-09-29 Revised:2024-12-05 Online:2024-12-28 Published:2024-12-28

摘要:

目的:探讨丁苯酞软胶囊治疗穿支动脉粥样硬化性脑梗死(BAD)合并早期抑郁症的临床疗效。方法:选取20221月至20231月于我院神经内科住院治疗的BAD合并早期抑郁症患者共72例作为研究对象,根据随机数字表分为观察组和对照组,每组各36例。对照组患者给予常规治疗,观察组患者在对照组治疗的基础上给予丁苯酞软胶囊治疗。治疗12周后,根据两组患者的汉密尔顿抑郁量表(HAMD)评分评价临床疗效,采用美国国立卫生研究院卒中量表(NIHSS)评分评估两组患者神经功能改善情况,采用Barhtel指数评定量表评估两组患者日常生活能力,并比较两组患者的不良反应发生情况。结果:观察组患者的治疗总有效率为94.44%,高于对照组的77.78%,差异有统计学意义(P<0.05)。治疗12周后,观察组患者的HAMD评分为(10.21±0.97)分,低于对照组的(18.46±2.15)分,差异有统计学意义(P<0.05);观察组患者的NIHSS评分为(3.02±0.32)分,低于对照组的(4.37±1.52)分,观察组患者的Barthel指数评分为(80.23±5.36)分,高于对照组的(60.72±4.24)分,差异均有统计学意义(P<0.05)。两组患者的不良反应发生率差异无统计学意义(P>0.05)。结论:丁苯酞软胶囊能够改善BAD患者的早期抑郁症状,促进神经功能恢复,提高患者生活质量。


关键词: 穿支动脉粥样硬化性脑梗死, 早期抑郁症, 丁苯酞软胶囊, 临床疗效

Abstract:

Objective: To investigate the clinical efficacy of butylphthalide soft capsules in the treatment of branch atheromatous disease BAD complicated with early depression.Methods: A total of 72 BAD patients complicated with early depression hospitalized in the department of neurology of our hospital from January 2022 to January 2023 were selected as the study subjects and were divided into the observation group and control group according to random number table with 36 cases in each group. The patients in the control group were treated with conventional treatment and the patients in the observation group were treated with butylphthalide soft capsules on the basis of the treatment in the control group. After 12 weeks of treatment the clinical efficacy of the two groups was evaluated according to the Hamilton Depression Rating Scale HAMD score. The improvement of neurological function of patients in the two groups was evaluated by the National Institutes of Health Stroke Scale NIHSS score. The daily living ability of patients in the two groups was evaluated by the Barhtel index rating scale and the occurrence of adverse reactions was compared between the two groups.Results: The total effective rate of the observation group was 94.44% which was higher than that of the control group 77.78%), and the difference was statistically significant χ2=4.181P<0.05. After 12 weeks of treatment the HAMD score of the observation group was10.21±0.97), which was lower than that of the control group18.46±2.15), and the difference was statistically significant P<0.05. The NIHSS score of the observation group was 3.02±0.32), which was lower than that of the control group 4.37±1.52), and the Barthel index score of the observation group was 80.23±5.36), which was higher than that of the control group 60.72±4.24), and the difference was statistically significant P<0.05. There was no statistic difference in the incidence of adverse reactions between the two groups P>0.05.Conclusion: Butylphthalide soft capsules can improve the early depressive symptoms of BAD patients promote the recovery of neurological function and improve the quality of life of patients.


Key words: Branch atheromatous disease , Early depression , Butylphthalide soft capsules , Clinical efficacy

中图分类号: